A Phase 1 Study Evaluating the Safety and Pharmacokinetic Profiles of IMC-3G3 Administered in a 2-week, or 3-week Schedule to Japanese Patients With Advanced Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Olaratumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 09 Feb 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
- 09 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Oct 2011 Planned end date changed from 1 Oct 2011 to 1 Nov 2011 as reported by ClinicalTrials.gov.